In less than 12 months, the collaboration between Chemotargets and Galyan Bio yields a scaffold for first-in-class clinical candidates in difficult area of neurodegenerative disease. Chemotargets employed its proprietary AI-driven…
With the new incorporation, the company consolidates its transition from a software business to an AI-driven biotech company. Barcelona, 6 October 2020 – Chemotargets, a global leader in predictive analytics…
This public-private partnership will establish a framework for collaboration that promotes the creation of synergies between both institutions. Chemotargets has entered into a strategic alliance with the IMIM Hospital del…
The Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) has licensed the Chemotargets CLARITY® platform for predicting unknown secondary targets for new molecules of pharmaceutical interest….
GENESIS Biomed and CREA Inversión will advise in the funding, which will allow the company to expand its activity in the discovery of new drugs. Barcelona, 14 April 2020 –…
The Seal of Excellence certifies the high-quality of the CLARITY proposal aimed at enhancing its data coverage, artificial intelligence approaches and analytics tools for drug discovery. Barcelona, July 11th, 2019….
The collaboration aims to enhance CDER’s safety assessments of human pharmaceuticals, supporting the FDA’s mission of protecting public health. Barcelona / Washington D.C., USA: The Food and Drug Administration’s Center…
Barcelona, May 2017 – Prous Institute for Biomedical Research announced today that it has made a strategic investment in Chemotargets SL. Founded by Dr. Jordi Mestres as a spin-off of…
© 2023 Chemotargets. Copyright and Legal Notice - Cookies Policy